Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Tamar Taddei, MD

Professor of Internal Medicine (Digestive Diseases); Vice Chief, Faculty Development, Digestive Diseases; Chief, Digestive Diseases, VA Connecticut Healthcare System

Contact Information

Tamar Taddei, MD

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), PO Box 208019

    New Haven, CT 06520-8019

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Taddei has built clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with liver cancer. In 2009, she developed the VA Connecticut Liver Tumor Board, now a regional tumor board serving VA Medical Centers in Connecticut, Rhode Island, Massachusetts, and Vermont. In 2011, she oversaw the accreditation of the Yale Liver Tumor Board, approved by the Smilow Cancer Hospital at Yale New Haven's Cancer Committee to meet all requirements of accreditation by the American College of Surgeons. She has been funded by the VA National Center for Patient Safety and the VA Office of HIV, Hepatitis and Related Conditions Programs for national implementation of the Coordinated Care Tracking System, a locally developed tool to improve liver cancer detection and comprehensive care. She is co-Principal Investigator of the Veteran's Outcomes and Costs Associated with Liver disease (VOCAL) study group, a national VA research consortium studying outcomes in Veterans with cirrhosis and liver cancer. She is co-Principal Investigator of the VA Clinical Science Research and Development (CSR&D)-funded randomized controlled trial of Statins in Cirrhosis - Reducing Events of Decompensation (SACRED). She is co-Chair of the VA Cooperative Studies Program (CSP)-funded randomized liver cancer screening trial, PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM).

 She collaborates on several translational projects that seek to understand the biology of liver cancer to inform prognosis and targets for treatment. She mentors trainees in research and considers this one of the most important and gratifying aspects of her career.

Specialized Terms: Clinical, translational, and outcome research on hepatocellular carcinoma

Coauthors

Research Interests

Delivery of Health Care; Digestive System Diseases; Carcinoma, Hepatocellular; Liver Cirrhosis; Translational Research, Biomedical

Public Health Interests

Health Care Quality, Efficiency; Health Care Management

Selected Publications

  • The risk of hepatocellular carcinoma is markedly increased in Gaucher diseaseBasiri M, Ruan J, Nair S, Lau H, Mistry P, Taddei T. The risk of hepatocellular carcinoma is markedly increased in Gaucher disease Molecular Genetics And Metabolism 2023, 138: 107022. DOI: 10.1016/j.ymgme.2022.107022.
  • When to Stop Screening—Liver CancerTaddei T, Jou J. When to Stop Screening—Liver Cancer The American Journal Of Gastroenterology 2022, 118: 427-428. PMID: 36563304, DOI: 10.14309/ajg.0000000000002120.
  • Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCCJaffe A, Taddei T, Giannini E, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC Liver International 2022, 43: 258-259. PMID: 36426717, DOI: 10.1111/liv.15482.
  • “Am I Going to Die?”: Delivering Serious News to Patients with Liver DiseasePatel A, Arnold R, Taddei T, Woodrell C. “Am I Going to Die?”: Delivering Serious News to Patients with Liver Disease Gastroenterology 2022 PMID: 36379246, DOI: 10.1053/j.gastro.2022.11.006.
  • COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosisJohn B, Bastaich D, Ferreira R, Doshi A, Taddei T, Kaplan D, Spector S, Deng Y, Dahman B. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis Gut 2022, gutjnl-2022-327799. DOI: 10.1136/gutjnl-2022-327799.
  • COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosisJohn B, Bastaich D, Ferreira R, Doshi A, Taddei T, Kaplan D, Spector S, Deng Y, Dahman B. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis Gut 2022, gutjnl-2022-327799. PMID: 36562753, DOI: 10.1136/gutjnl-2022-327799.
  • Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination toolZhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Ciarleglio M, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose M, Taddei T. Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool PLOS Digital Health 2022, 1: e0000080. DOI: 10.1371/journal.pdig.0000080.
  • Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination toolZhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Ciarleglio M, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose M, Taddei T. Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool PLOS Digital Health 2022, 1: e0000080. PMID: 36812575, PMCID: PMC9931271, DOI: 10.1371/journal.pdig.0000080.
  • THU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosisJohn B, Doshi A, Deng Y, Mansour N, Barritt A, Moon A, Ioannou G, Martin P, Chao H, Taddei T, Kaplan D, Dahman B. THU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis Journal Of Hepatology 2022, 77: s223. PMCID: PMC9252350, DOI: 10.1016/s0168-8278(22)00818-2.
  • THU270 Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variantJohn B, Ferreira R, Bastaich D, Doshi A, Taddei T, Kaplan D, Spector S, Dahman B. THU270 Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant Journal Of Hepatology 2022, 77: s227. PMCID: PMC9252347, DOI: 10.1016/s0168-8278(22)00826-1.
  • OS126 The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a veterans affairs cohort studyMahmud N, Serper M, Taddei T, Kaplan D. OS126 The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a veterans affairs cohort study Journal Of Hepatology 2022, 77: s89-s90. DOI: 10.1016/s0168-8278(22)00572-4.
  • 782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSISJohn B, Doshi A, Ferreira R, Taddei T, Kaplan D, Deng Y, Chao H, Dahman B. 782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS Gastroenterology 2022, 162: s-1137. PMCID: PMC9212541, DOI: 10.1016/s0016-5085(22)63413-9.
  • Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSISJohn B, Doshi A, Deng Y, Mansour N, Barritt A, Moon A, Ioannou G, Martin P, Chao H, Taddei T, Kaplan D, Dahman B. Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS Gastroenterology 2022, 162: s-1248. PMCID: PMC9212545, DOI: 10.1016/s0016-5085(22)63679-5.
  • Effect of a cancer tracking system on timeliness of liver cancer care at a Veteran's Hospital.Ivatorov A, Mezzacappa C, Taddei T. Effect of a cancer tracking system on timeliness of liver cancer care at a Veteran's Hospital. Journal Of Clinical Oncology 2022, 40: 406-406. DOI: 10.1200/jco.2022.40.4_suppl.406.
  • Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and CirrhosisJohn BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.
  • 237 OBETICHOLIC ACID EXPOSURE IS ASSOCIATED WITH HEPATIC DECOMPENSATION IN SUBJECTS WITH PRIMARY BILIARY CHOLANGITIS AND CIRRHOSISJohn B, Schwartz K, Levy C, Dahman B, Deng Y, Martin P, Taddei T, Kaplan D. 237 OBETICHOLIC ACID EXPOSURE IS ASSOCIATED WITH HEPATIC DECOMPENSATION IN SUBJECTS WITH PRIMARY BILIARY CHOLANGITIS AND CIRRHOSIS Gastroenterology 2021, 160: s-769-s-770. DOI: 10.1016/s0016-5085(21)02551-8.
  • 171 LIVER TRANSPLANTATION EVALUATION BY TELEMEDICINE IS ASSOCIATED WITH EXPEDITED EVALUATION AND LISTINGJohn B, Deng Y, Kaplan D, Taddei T, Dahman B. 171 LIVER TRANSPLANTATION EVALUATION BY TELEMEDICINE IS ASSOCIATED WITH EXPEDITED EVALUATION AND LISTING Gastroenterology 2021, 160: s-765-s-766. DOI: 10.1016/s0016-5085(21)02542-7.
  • SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of DecompensationKaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.
  • Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.
  • Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and CirrhosisKaplan DE, Serper M, John BV, Tessiatore KM, Lerer R, Mehta R, Fox R, Aytaman A, Baytarian M, Hunt K, Albrecht J, Taddei TH, Group V. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis Clinical Gastroenterology And Hepatology 2020, 19: 2148-2160.e14. PMID: 32798709, DOI: 10.1016/j.cgh.2020.08.026.
  • FRI129 Ursodeoxycholic acid response in primary biliary cholangitis is associated with a significant reduction in decompensation and mortality in compensated cirrhosisJohn B, Khakoo N, Aitcheson G, Levy C, Goldberg D, Bhamidimarri K, Hernandez M, Dahman B, Deng Y, Martin P, Taddei T, Kaplan D. FRI129 Ursodeoxycholic acid response in primary biliary cholangitis is associated with a significant reduction in decompensation and mortality in compensated cirrhosis Journal Of Hepatology 2020, 73: s462. DOI: 10.1016/s0168-8278(20)31407-0.
  • FRI130 Male gender is associated with a high rate of decompensation and mortality in primary biliary cholangitis with well compensated cirrhosisJohn B, Khakoo N, Aitcheson G, Levy C, Goldberg D, Bhamidimarri K, Hernandez M, Dahman B, Deng Y, Martin P, Taddei T, Kaplan D. FRI130 Male gender is associated with a high rate of decompensation and mortality in primary biliary cholangitis with well compensated cirrhosis Journal Of Hepatology 2020, 73: s463. DOI: 10.1016/s0168-8278(20)31408-2.
  • Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular CarcinomaZhang Y, Weinreb J, Czeyda-Pommersheim F, Taddei T. Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular Carcinoma Journal Of The American College Of Radiology 2020, 17: 1636-1643. PMID: 32533924, DOI: 10.1016/j.jacr.2020.05.003.
  • An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.
  • Su1645 MALES GENDER IS ASSOCIATED WITH A HIGH RATE OF DECOMPENSATION AND MORTALITY IN PRIMARY BILIARY CHOLANGITIS WITH WELL COMPENSATED CIRRHOSISJohn B, Khakoo N, Aitcheson G, Levy C, Goldberg D, Bhamidimarri K, Hernandez M, Dahman B, Deng Y, Martin P, Taddei T, Kaplan D. Su1645 MALES GENDER IS ASSOCIATED WITH A HIGH RATE OF DECOMPENSATION AND MORTALITY IN PRIMARY BILIARY CHOLANGITIS WITH WELL COMPENSATED CIRRHOSIS Gastroenterology 2020, 158: s-1372. DOI: 10.1016/s0016-5085(20)34098-1.
  • Su1640 URSODEOXYCHOLIC ACID RESPONSE IN PRIMARY BILIARY CHOLANGITIS IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN DECOMPENSATION AND MORTALITY IN COMPENSATED CIRRHOSISJohn B, Khakoo N, Aitcheson G, Levy C, Goldberg D, Bhamidimarri K, Hernandez M, Dahman B, Deng Y, Martin P, Taddei T, Kaplan D. Su1640 URSODEOXYCHOLIC ACID RESPONSE IN PRIMARY BILIARY CHOLANGITIS IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN DECOMPENSATION AND MORTALITY IN COMPENSATED CIRRHOSIS Gastroenterology 2020, 158: s-1369-s-1370. DOI: 10.1016/s0016-5085(20)34093-2.
  • Palliative Care in Cirrhosis: Beyond MisconceptionsJakab S, Verma M, Navarro V, Taddei T. Palliative Care in Cirrhosis: Beyond Misconceptions Current Treatment Options In Gastroenterology 2020, 18: 245-254. DOI: 10.1007/s11938-020-00283-1.
  • Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 ScoresIoannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores Gastroenterology 2019, 157: 1264-1278.e4. PMID: 31356807, PMCID: PMC6815714, DOI: 10.1053/j.gastro.2019.07.033.
  • Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortalityMahmud N, John B, Taddei T, Goldberg DS. Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality Clinical Transplantation 2019, 33: e13634. PMID: 31177570, PMCID: PMC6635076, DOI: 10.1111/ctr.13634.
  • 351 – Cancer Tracking System Improves Timeliness of Liver Cancer Care At a Veterans HospitalZhang Y, Mehta R, Taddei T. 351 – Cancer Tracking System Improves Timeliness of Liver Cancer Care At a Veterans Hospital Gastroenterology 2019, 156: s-1192. DOI: 10.1016/s0016-5085(19)39956-1.
  • 680 – Elevated Hcc Risk Persists for Up to 10 Years After Hepatitis C Eradication in Patients with Baseline Cirrhosis and Elevated Fib-4 ScoreIoannou G, Singal A, Tapper E, Waljee A, Sterling R, Feld J, Kaplan D, Taddei T, Beste L, Green P, Berry K. 680 – Elevated Hcc Risk Persists for Up to 10 Years After Hepatitis C Eradication in Patients with Baseline Cirrhosis and Elevated Fib-4 Score Gastroenterology 2019, 156: s-1209. DOI: 10.1016/s0016-5085(19)40006-1.
  • Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment StrategiesSaffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies Digestive Diseases And Sciences 2019, 64: 1016-1029. PMID: 30887150, DOI: 10.1007/s10620-019-05582-x.
  • Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular PearlsCostantino A, Taddei T. Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls Current Hepatology Reports 2018, 17: 412-424. DOI: 10.1007/s11901-018-0426-6.
  • Sa1443 - Effect of Weekend Admission for Acute Liver Failure: Analysis of the National Inpatient SampleDo A, Taddei T, Ilagan-Ying Y. Sa1443 - Effect of Weekend Admission for Acute Liver Failure: Analysis of the National Inpatient Sample Gastroenterology 2018, 154: s-1115. DOI: 10.1016/s0016-5085(18)33710-7.
  • THU-154 Risk-stratified management of advanced hepatocellular carcinoma (HCC)Pinato D, Kaplan D, Yen C, Rimassa L, Dominik B, Pressiani T, Thimme R, Pirisi M, Burlone M, Arizumi T, Kudo M, Park J, Taddei T, Johnson P, Sharma R. THU-154 Risk-stratified management of advanced hepatocellular carcinoma (HCC) Journal Of Hepatology 2018, 68: s196. DOI: 10.1016/s0168-8278(18)30604-4.
  • Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity MatchingKaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.
  • Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy.Zhang Y, Arango J, Weinreb J, Taddei T. Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy. Journal Of Clinical Oncology 2018, 36: 259-259. DOI: 10.1200/jco.2018.36.4_suppl.259.
  • The effect of socioeconomic factors on the outcome of hepatocellular carcinoma.Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.
  • Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinomaKaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.
  • Palliative care in decompensated cirrhosis: A reviewLangberg KM, Kapo JM, Taddei TH. Palliative care in decompensated cirrhosis: A review Liver International 2018, 38: 768-775. PMID: 29112338, DOI: 10.1111/liv.13620.
  • Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United StatesKaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.
  • Mo1383 Weight Change After Receipt of Direct-Acting Antiviral Agents for Hepatitis CDo A, Esserman D, Tate J, Njei B, Levin F, Lim J, Taddei T, Justice A. Mo1383 Weight Change After Receipt of Direct-Acting Antiviral Agents for Hepatitis C Gastroenterology 2017, 152: s1163. DOI: 10.1016/s0016-5085(17)33893-3.
  • Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVESButt AA, Ren Y, Re V, Taddei T, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES Clinical Infectious Diseases 2017, 65: 64-72. PMID: 28369305, DOI: 10.1093/cid/cix224.
  • Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain disseminationVilarinho S, Erson-Omay E, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH. Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination Journal Of Hepatology 2017, 67: 186-191. PMID: 28323122, PMCID: PMC5497691, DOI: 10.1016/j.jhep.2017.03.009.
  • Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and MortalitySerper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.
  • Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.
  • Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.
  • Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.
  • HIV, Aging, and Viral Coinfections: Taking the Long ViewTaddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.
  • Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with CirrhosisKaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T, for the VOCAL Study Group. Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis Digestive Diseases And Sciences 2016, 61: 3309-3320. PMID: 27405990, PMCID: PMC5067291, DOI: 10.1007/s10620-016-4239-6.
  • Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma?Taddei T. Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma? Hepatology 2016, 63: 1078-1079. PMID: 26764271, DOI: 10.1002/hep.28452.
  • Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare DatabaseKaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Knott A, Pedrosa M, Pocha C, Mehta R, Duggal M, Skanderson M, Valderrama A, Taddei TH, Group V. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database Clinical Gastroenterology And Hepatology 2015, 13: 2333-2341.e6. PMID: 26188137, PMCID: PMC4655141, DOI: 10.1016/j.cgh.2015.07.010.
  • Using a European Value-Based Medicine Approach to Evaluate Hepatocellular Carcinoma Care at a US Tertiary Care Center.Loo N, Taddei T. Using a European Value-Based Medicine Approach to Evaluate Hepatocellular Carcinoma Care at a US Tertiary Care Center. Journal Of Clinical Oncology 2015, 33: e15118-e15118. DOI: 10.1200/jco.2015.33.15_suppl.e15118.
  • Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic EvidenceNjei B, Schilsky M, Ditah I, Taddei T. Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic Evidence Gastroenterology 2015, 148: s-1036. DOI: 10.1016/s0016-5085(15)33541-1.
  • Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010.Kaplan D, Taddei T, Aytaman A, Hunt K, Knott A, Dieperink E, Baytarian M, Fox R, Pedrosa M, D'Addeo K, Dai F, Mehta R, Duggal M, Pocha C, Skanderson M, Valderrama A. Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010. Journal Of Clinical Oncology 2015, 33: 243-243. DOI: 10.1200/jco.2015.33.3_suppl.243.
  • Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare DatabaseKaplan D, Taddei T, Skanderson M, Pocha C, Pedrosa M, Mehta R, Knott A, Hunt K, Fox R, Duggal M, Dai F, D K, Baytarian M, Valderrama A, Aytaman A. Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare Database Gastroenterology 2014, 146: s-992. DOI: 10.1016/s0016-5085(14)63605-2.
  • Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010Taddei T, Kaplan D, Aytaman A, Baytarian M, D K, Dai F, Duggal M, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Skanderson M. Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010 Gastroenterology 2014, 146: s-998. DOI: 10.1016/s0016-5085(14)63627-1.
  • EMR-linked cancer tracker facilitates lung and liver cancer care.Taddei T, Hunnibell L, DeLorenzo A, Rosa M, Connery D, Vogel D, Garla V, Taylor C, Rose M. EMR-linked cancer tracker facilitates lung and liver cancer care. Journal Of Clinical Oncology 2012, 30: 77-77. DOI: 10.1200/jco.2012.30.34_suppl.77.
  • THE EFFICACY OF WEIGHT REDUCTION IN NONALCOHOLIC FATTY LIVER DISEASETaddei T, Younossi Z. THE EFFICACY OF WEIGHT REDUCTION IN NONALCOHOLIC FATTY LIVER DISEASE Evidence-Based Gastroenterology 2004, 5: 96-97. DOI: 10.1097/00132579-200408000-00012.
Edit Profile